Easy Start Sample Program

• Should Your Patient Be Tested
• Your Newly Diagnosed Patient
• Managing Your AAT Deficient Patient

Baxter is offering Alpha-1 patients (who have not previously used ARALAST) and their physicians the opportunity to receive up to a two-week sample supply for a no-charge trial.

To initiate the process to receive a complimentary two-week trial sample of ARALAST, please call 1-866-ARALAST (272-5278).

You can have confidence in Baxter's...

• Commitment to a reliable supply of ARALAST
• Distribution of ARALAST through Specialized Pharmacy Providers who provide comprehensive in-home care
• Support for the Alpha-1 community through continued AAT deficiency research
• Patient Assistance programs, including Baxter's ARA-ASSIST Program

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A₁-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A₁-PI deficiency has not been established.

Important Safety Information

• ARALAST is contraindicated in individuals with selective IgA deficiencies (IgA level less than 15mg/dL) who have known antibody against IgA, since they may experience severe reactions, including a severe, potentially life-threatening allergic reaction to IgA, which may be present.
• ARALAST is made from human plasma. It may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
• The most common symptoms during the clinical study were headache (0.3%) and sleepiness (0.3%). Post market adverse event data have indicated reports of infusion site pain associated with the administration of ARALAST.

Please review the Important Safety Information and the Full Prescribing Information